Patents by Inventor Uwe Schwahn
Uwe Schwahn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230265152Abstract: The present invention relates to fusion proteins comprising a Glucagon-Like Peptide-1 Receptor 5 (GLP-1R) agonistic peptide and a variant of human Fibroblast Growth Factor 21 (FGF21). The present invention further relates to the use of fusion proteins comprising a GLP-1R agonistic peptide and a variant of FGF21 as medicaments, in particular for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopathy, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and/or atherosclerosis in a subject. The present invention also relates to pharmaceutical compositions comprising fusion proteins including a GLP-1R agonistic peptide and a variant of FGF21.Type: ApplicationFiled: July 2, 2020Publication date: August 24, 2023Inventors: Oliver BOSCHEINEN, Werner DITTRICH, Andreas EVERS, Thomas LANGER, Christine RUDOLPH, Uwe SCHWAHN, Mark SOMMERFELD
-
Publication number: 20230250147Abstract: The present invention relates to Glucagon-Like Peptide-1 Receptor (GLP-1R) agonistic peptides with reduced GLP-1R CA agonistic activity, and fusion molecules comprising the same. The present invention also relates to nucleic acid molecules encoding GLP-1R agonistic peptides with reduced GLP-1R agonistic activity, pharmaceutical compositions and combinations comprising GLP-1R agonistic peptides with reduced GLP-1R agonistic activity, and kits including GLP-1R agonistic peptides with reduced GLP-1R agonistic activity. The present invention further relates to the use of GLP-1R agonistic peptides with reduced GLP-1R agonistic activity as medicaments, in particular, for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopa-CA thy, hyperglycemia, dyslipidemia, NASH and/or atherosclerosis.Type: ApplicationFiled: July 2, 2020Publication date: August 10, 2023Inventors: Oliver BOSCHEINEN, Werner DITTRICH, Andreas EVERS, Thomas LANGER, Christine RUDOLPH, Uwe SCHWAHN, Mark SOMMERFELD
-
Publication number: 20220010021Abstract: Provided herein are FGFR1/KLB targeting agonistic antigen-binding proteins, or fragments thereof, having improved physico-chemical properties. Also provided herein are conjugates comprising an FGFR1/KLB targeting agonistic antigen-binding protein, or a fragment thereof, and at least one GLP-1R agonistic peptide. Further provided are pharmaceutical compositions comprising the antibody (or fragment thereof), or the conjugate provided herein, and the use of the antibody (or fragment thereof, or the use of the conjugate in medicine.Type: ApplicationFiled: July 1, 2021Publication date: January 13, 2022Inventors: Mark SOMMERFELD, Thomas LANGER, Uwe SCHWAHN, Werner DITTRICH, Christine RUDOLPH, Matthias DREYER, Soraya HÖLPER, Christian LANGE, Katrin LORENZ
-
Patent number: 10995150Abstract: The present invention provides methods and compositions for inhibiting atherosclerotic plaque formation in a subject. In certain embodiments, the methods of the present invention comprise selecting a subject who has, or is at risk of developing, atherosclerosis, and administering to the subject a pharmaceutical composition comprising a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody, or antigen binding protein.Type: GrantFiled: July 8, 2019Date of Patent: May 4, 2021Assignees: REGENERON PHARMACEUTICALS, INC., SANOFI BIOTECHNOLOGYInventors: William J. Sasiela, Viktoria Gusarova, Anusch Peyman, Hans Ludwig Schäfer, Uwe Schwahn
-
Publication number: 20200071422Abstract: The present invention provides methods and compositions for inhibiting atherosclerotic plaque formation in a subject. In certain embodiments, the methods of the present invention comprise selecting a subject who has, or is at risk of developing, atherosclerosis, and administering to the subject a pharmaceutical composition comprising a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody, or antigen binding protein.Type: ApplicationFiled: July 8, 2019Publication date: March 5, 2020Inventors: William J. Sasiela, Viktoria Gusarova, Anusch Peyman, Hans Ludwig Schäfer, Uwe Schwahn
-
Patent number: 10494442Abstract: The present invention provides methods and compositions for inhibiting atherosclerotic plaque formation in a subject. In certain embodiments, the methods of the present invention comprise selecting a subject who has, or is at risk of developing, atherosclerosis, and administering to the subject a pharmaceutical composition comprising a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody, or antigen binding protein.Type: GrantFiled: June 6, 2014Date of Patent: December 3, 2019Assignees: SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC.Inventors: William J. Sasiela, Viktoria Gusarova, Anusch Peyman, Hans Ludwig Schäfer, Uwe Schwahn
-
Publication number: 20180244801Abstract: The present invention provides methods and compositions for inhibiting atherosclerotic plaque formation in a subject. In certain embodiments, the methods of the present invention comprise selecting a subject who has, or is at risk of developing, atherosclerosis, and administering to the subject a pharmaceutical composition comprising a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. In certain embodiments, this PCSK9 inhibitor is an anti-PCSK9 antibody, or antigen binding protein.Type: ApplicationFiled: January 18, 2018Publication date: August 30, 2018Inventors: William J. Sasiela, Viktoria Gusarova, Anusch Peyman, Hans-ludwig Schaefer, Uwe Schwahn
-
Publication number: 20160115246Abstract: The present invention provides methods and compositions for inhibiting atherosclerotic plaque formation in a subject. In certain embodiments, the methods of the present invention comprise selecting a subject who has, or is at risk of developing, atherosclerosis, and administering to the subject a pharmaceutical composition comprising a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody, or antigen binding protein.Type: ApplicationFiled: June 6, 2014Publication date: April 28, 2016Inventors: William J. Sasiela, Viktoria Gusarova, Anusch Peyman, Hans-ludwig Schaefer, Uwe Schwahn
-
Publication number: 20140065649Abstract: The present invention relates to methods for the identification and characterization of therapeutic candidates for use in the treatment of a disease or condition associated with elevated LDL-C levels involving a rodent, methods for the testing of the efficacy of an antibody specifically binding to proprotein convertase subtilisin/kexin type 9 (PCSK9) involving a rodent, as well as a rodent and its use in the identification or profiling of compounds for modulation of a disease or condition associated with elevated LDL-C levels.Type: ApplicationFiled: April 30, 2012Publication date: March 6, 2014Applicant: SanofiInventors: Hans-Ludwig Schaefer, Eugen Falk, Uwe Schwahn
-
Publication number: 20120282710Abstract: The present invention relates to an isolated protein comprising a ligand binding domain of a nuclear receptor in controllable form, a method of producing the same, its use for the identification of a ligand, a test system comprising the isolated protein and a method for screening for a ligand for a nuclear receptor using the test system.Type: ApplicationFiled: July 17, 2012Publication date: November 8, 2012Applicant: SANOFIInventors: Uwe SCHWAHN, Thomas LANGER
-
Publication number: 20120202795Abstract: The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I: wherein R, R1, R2, R3 and R4 are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5?-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.Type: ApplicationFiled: April 18, 2012Publication date: August 9, 2012Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: Philip M. WEINTRAUB, Paul R. EASTWOOD, Shujaath MEHDI, David W. STEFANY, Kwon Yon MUSICK, Neil MOORCROFT, Sungtaek LIM, John Z. JIANG, Hartmut RUTTEN, Stefan PEUKERT, Uwe SCHWAHN
-
Patent number: 8173682Abstract: The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I: wherein R, R1, R2, R3 and R4 are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5?-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.Type: GrantFiled: September 26, 2006Date of Patent: May 8, 2012Assignee: Aventis Pharmaceuticals Inc.Inventors: Philip M. Weintraub, Paul R. Eastwood, Shujaath Mehdi, David W. Stefany, Kwon Yon Musick, Neil Moorcroft, Sungtaek Lim, John Z. Jiang, Hartmut Rutten, Stefan Peukert, Uwe Schwahn
-
Publication number: 20110177611Abstract: The present invention relates to an isolated protein comprising a ligand binding domain of a nuclear receptor in controllable form, a method of producing the same, its use for the identification of a ligand, a test system comprising the isolated protein and a method for screening for a ligand for a nuclear receptor using the test system.Type: ApplicationFiled: September 13, 2008Publication date: July 21, 2011Applicant: SANOFI-AVENTISInventors: Uwe Schwahn, Thomas Langer
-
Publication number: 20110021462Abstract: This invention relates to compounds according to the general formula (I), where the definitions of the substituents R1, R2, Ar and X are as specified in the description, and to their physiologically tolerated salts, methods for the preparation of these compounds and their use as medicaments. These compounds are poly(ADP-ribose) polymerase (PARP) inhibitors.Type: ApplicationFiled: August 4, 2010Publication date: January 27, 2011Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Stefan PEUKERT, Stefan GUESSREGEN, Armin HOFMEISTER, Herman SCHREUDER, Uwe SCHWAHN
-
Patent number: 7863280Abstract: This invention relates to compounds of formula (I), wherein R1 and R3 independently represent fluorine, methoxy, —OCF3, C2-C3-alkenyl or C1-C4-alkyl which is optionally substituted by chlorine, methoxy or one, two or three fluorine atoms; R2 represents hydrogen, fluorine, methoxy, —OCF3, C2-C3-alkenyl or C1-C4-alkyl which is optionally substituted by chlorine, methoxy or one, two or three fluorine atoms; X represents O, S, NH or N(C1-C3-alkyl); and Ar represents an unsubstituted or at least monosubstituted aryl or heteroaryl. Said compounds are inhibitors of poly(ADP-ribose) polymerase (PARP), and may be used for the treatment of a variety of disorders.Type: GrantFiled: April 11, 2007Date of Patent: January 4, 2011Assignee: Sanofi-Aventis Deutschland GmbHInventors: Stefan Peukert, Stefan Guessregen, Armin Hofmeister, Herman Schreuder, Uwe Schwahn
-
Patent number: 7795278Abstract: This invention relates to compounds according to the general formula (I), where the definitions of the substituents R1, R2, Ar and X are as specified in the description, and to their physiologically tolerated salts, methods for the preparation of these compounds and their use as medicaments. These compounds are poly(ADP-ribose) polymerase (PARP) inhibitors.Type: GrantFiled: December 6, 2006Date of Patent: September 14, 2010Assignee: sanofi-aventis Deutschland GmbHInventors: Stefan Peukert, Stefan Guessregen, Armin Hofmeister, Herman Schreuder, Uwe Schwahn
-
Publication number: 20070281948Abstract: This invention relates to compounds of formula (I), wherein R1 and R3 independently represent fluorine, methoxy, —OCF3, C2-C3-alkenyl or C1-C4-alkyl which is optionally substituted by chlorine, methoxy or one, two or three fluorine atoms; R2 represents hydrogen, fluorine, methoxy, —OCF3, C2-C3-alkenyl or C1-C4-alkyl which is optionally substituted by chlorine, methoxy or one, two or three fluorine atoms; X represents O, S, NH or N(C1-C3-alkyl); and Ar represents an unsubstituted or at least monosubstituted aryl or heteroaryl. Said compounds are inhibitors of poly(ADP-ribose) polymerase (PARP), and may be used for the treatment of a variety of disorders.Type: ApplicationFiled: April 11, 2007Publication date: December 6, 2007Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Stefan PEUKERT, Stefan GUESSREGEN, Armin HOFMEISTER, Hermann SCHREUDER, Uwe SCHWAHN
-
Publication number: 20070142430Abstract: This invention relates to compounds according to the general formula (I), where the definitions of the substituents R1, R2, Ar and X are as specified in the description, and to their physiologically tolerated salts, methods for the preparation of these compounds and their use as medicaments. These compounds are poly(ADP-ribose) polymerase (PARP) inhibitors.Type: ApplicationFiled: December 6, 2006Publication date: June 21, 2007Applicant: sanofi-aventis Deutschland GmbHInventors: Stefan PEUKERT, Stefan GUESSREGEN, Armin HOFMEISTER, Herman SCHREUDER, Uwe SCHWAHN
-
Publication number: 20070032489Abstract: The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I: wherein R, R1, R2, R3 and R4 are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5?-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.Type: ApplicationFiled: September 26, 2006Publication date: February 8, 2007Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: Philip Weintraub, Paul Eastwood, Shujaath Mehdi, David Stefany, Kwon Musick, Neil Moorcroft, Sungtaek Lim, John Jiang, Hartmut Rutten, Stefan Peukert, Uwe Schwahn